Your browser doesn't support javascript.
loading
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma.
Bedke, Jens; Albiges, Laurence; Capitanio, Umberto; Giles, Rachel H; Hora, Milan; Ljungberg, Börje; Marconi, Lorenzo; Klatte, Tobias; Volpe, Alessandro; Abu-Ghanem, Yasmin; Dabestani, Saeed; Fernández-Pello, Sergio; Hofmann, Fabian; Kuusk, Teele; Tahbaz, Rana; Powles, Thomas; Bex, Axel.
Afiliação
  • Bedke J; Department of Urology, University Hospital Tübingen, Tübingen, Germany; German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany.
  • Albiges L; Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Capitanio U; Department of Urology, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy.
  • Giles RH; International Kidney Cancer Coalition, Duivendrecht, The Netherlands.
  • Hora M; Department of Urology, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Czech Republic.
  • Ljungberg B; Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
  • Marconi L; Department of Urology, Coimbra University Hospital, Coimbra, Portugal.
  • Klatte T; Department of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Volpe A; Department of Urology, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy.
  • Abu-Ghanem Y; Department of Urology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
  • Dabestani S; Department of Translational Medicine, Division of Urological Cancers, Lund University, Malmö, Sweden.
  • Fernández-Pello S; Department of Urology, Cabueñes University Hospital, Gijón, Spain.
  • Hofmann F; Department of Urology, Sunderby Sjukhus, Umeå University, Luleå, Sweden.
  • Kuusk T; Department of Urology, Homerton University Hospital, London, UK.
  • Tahbaz R; Department of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Powles T; The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Bex A; The Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: a.bex@ucl.ac.uk
Eur Urol ; 83(1): 10-14, 2023 01.
Article em En | MEDLINE | ID: mdl-36511268
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Eur Urol Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Eur Urol Ano de publicação: 2023 Tipo de documento: Article